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Background: Cytomegalovirus (CMV) are ubiquitously distributed worldwide, causing a wide range of
clinical manifestations from congenital infection to a life-threatening disease in immunocompromised
individuals. CMV can be transmitted via human-to-human contact through body fluids; however, the risk
of CMV infection among healthcare workers (HCWs) has not been fully evaluated.
Aim: This study aimed to assess the risk of CMV infection among HCWs through daily medical practices.
Methods: Serum samples from HCWs at Osaka University Hospital (Japan) were analysed. Initially, we
compared CMV IgG seropositivity among HCWs (medical doctors, nurses, and others) in 2017, which was
examined after 1 year to evaluate seroconversion rates among those with seronegative results. Then, we
examined CMV seroconversion rates in HCWs who were exposed to blood and body fluids.
Findings: We analysed 1153 samples of HCWs (386 medical doctors, 468 nurses, and 299 others), of
which CMV seropositivity rates were not significantly different (68.9%, 70.3%, and 70.9%, respectively). Of
these, 63.9% (221/346) of CMV seronegative HCWs were followed after 1 year, with CMV seroconversion
rates of 3.2% (7/221). Among 72 HCWs who tested negative for CMV IgG when exposed to blood and
body fluids, the CMV seroconversion rate was 2.8% (2/72). The CMV seroconversion rates between the
two situations were not significantly different.
Conclusion: Our study indicated that CMV infection through daily patient care seems quite rare. Further
well-designed studies with a large sample size are warranted to verify our finding.
© 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Cytomegalovirus (CMV) is one of the most common human
herpesvirus that prevails worldwide, with seroprevalence ranging
from 45% to 100% in the general population [1]. Patients with CMV
latent infection unknowingly shed the virus in their urine, saliva,
blood, vaginal discharge, semen, stool, and breastmilk, and human-
to-human transmission involves contact with CMV-infected blood
or body fluids by healthy individuals. CMV causes asymptomaticve ICMJE authorship criteria.
trol and Prevention, Osaka
5-0871, Japan.
a).
d The Japanese Association for Infectiinfection but possibly creates a serious burden, such as congenital
CMV infection [2,3].
Healthcare workers (HCWs) frequently encounter various in-
fectious agents, such as hepatitis B and C viruses and human im-
munodeficiency virus, through blood and body fluid exposure
(BBFE). However, there are no relevant data on the risk of CMV
infection amongHCWs. The prevalence of the anti-CMV antibody in
the general population is reportedly high; 83% of the global general
population [4], 76.6% of Japanese blood donors [5], and 56.7% of the
German population [6] were CMV positive. These studies reported
that CMV seroprevalence increases with ageing, which could be
attributed to the improvement in public sanitation and hygiene
practices. This situation, i.e. a growing number of CMV-susceptible
young individuals, may possibly place HCWs at risk of CMVous Diseases. Published by Elsevier Ltd. All rights reserved.
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of CMV infection among HCWs.
2. Materials and methods
This study was conducted at Osaka University Hospital, an ac-
ademic, tertiary medical facility in Japan. This study was approved
by the Institutional Review Board of Osaka University Hospital (No.
10105e2 and 11183e2). Informed consent was waived because the
samples were retrospectively measured after de-identifying the
information of the study participants.
The study constitutes two different parts to compare CMV
seroconversion rates between HCWs with BBFE and those without
BBFE. First, we conducted a comparison of CMV seropositivity
among three different job categories of HCWs (medical doctors,
nurses, and others [pharmacists, medical clerks, and nutrition ex-
perts]) with a 1-year follow-up (Study 1). Second, we investigated
the CMV IgG seroconversion rates following BBFE (Study 2). In the
first part, we analysed serum samples of HCWs that were submit-
ted and preserved at our clinical laboratory for the purpose of
annual medical checkups. Serum samples obtained in June 2017
and June 2018 were used to assess seroconversion rates in a year
through a natural course. HCWs, who reported BBFEs during the
study period were excluded. In the second part, we used serum
samples of HCWs after BBFE and those of exposure sources. Be-
tween January 2013 andMarch 2018, therewere 401 reported cases
of BBFE at our facility. Of these, we regarded cases as eligible when
the exposed HCWs were negative for the CMV antibody, and the
exposure sources were positive for CMV. The flow of the two
studies is presented in Fig. 1. In this study, we tested for CMV
positivity by examining the anti-CMV antibody, for both the
exposed HCWs and the exposure sources, using Alinity CMV-G
(Abbott Diagnostic Division, Tokyo, Japan) with a cutoff level of
6.0 AU/mL according to the manufacturer's instructions. The sam-
ples had been stored at 60 C before measurement.
Continuous variables were reported as medians and inter-
quartile ranges (IQRs) and assessed using the ManneWhitney U
test or KruskaleWallis test with Bonferroni adjustment. Categorical
variables were reported as numbers and percentages and assessed
using Fisher's exact test. Statistical analysis was performed usingFig. 1. Flow of the study. Study 1: CMV seroconversion rate through natural courses. Stud
follows: exposed HCWs being negative for CMV and exposure sources being positive for CMthe EZR software, a graphical user interface for the R 3.5.2 software
(The R Foundation for Statistical Computing, Vienna, Austria) [7].
All reported P-values < 0.05 were considered statistically
significant.
3. Results
3.1. Study 1: CMV seroconversion rate through natural courses
(Table 1)
We analysed samples from 1153 HCWs, of which there were 447
men and 706 women. There were 386 doctors, 468 nurses, and 299
other HCWs. The median age (IQR) of nurses (31 [23, 43.25]) was
significantly lower than those of medical doctors (38 [33, 46]) and
others (41 [32, 47.5]) (p < 0.001). CMV positivity rates increased by
10-year age group: 61.1% in <30 years, 69.6% in 30 to <40 years,
73.3% in 40 to <50 years, 79.6% in 50 to <60 years, and 88.2% in 60
to <65 years (Supple Table 1). Of these, CMV positivity rates in all
HCWs, medical doctors, nurses, and others were 70.0%, 68.9%,
70.3%, and 70.9%, respectively, in which there was no significant
difference among the three occupational categories (p ¼ 0.84).
Of 346 CMV seronegative HCWs in June 2017, 63.9% (221 in total;
72 medical doctors, 78 nurses, and 71 others) were followed after 1
year (June 2018) to examine the CMV seroconversion rates in their
natural courses. Similar to those examined 1 year before, the me-
dian age (IQR) of nurses (33.5 [24, 44]) was significantly lower than
those of medical doctors (40 [34, 45]) and others (39 [31.5, 44])
(p < 0.001). As a result, CMV seroconversion rates in medical doc-
tors, nurses, and other HCWs were 2.8% (2/72), 2.6% (2/78), and
4.2% (3/71), respectively. Statistical analysis revealed no significant
difference in the CMV seroconversion rates among these job cate-
gories (p ¼ 0.80).
3.2. Study 2: CMV seroconversion rates after BBFE (Table 2)
For those who were exposed to blood and body fluids of pa-
tients, there were 119 CMV seronegative HCWs at the time of
exposure (29.7%). Of these, 12 cases were excluded because the
source of exposure tested negative for the CMV antibody. Finally,
107 cases (26.7%) were selected for follow-up as eligible cases, ofy 2: CMV seroconversion rates after BBFE. *In Study 2, the inclusion criteria were as
V. BBFE, blood and body fluid exposure; CMV, cytomegalovirus.
Table 1
Cytomegalovirus (CMV) antibody positivity of 1153 serum samples obtained from healthcare workers of Osaka University Hospital in 2017 and seroconversion rates after one
year.
Total Medical doctors Nurses aOthers
CMV positivity in 2017
Number 1153 386 468 299
Men/women 447/706 308/78 50/418 89/210
Median age (interquartile range) (yr) 36 (28, 46) 38 (33, 46) 31 (23, 43.25) 41 (32, 47.5)











CMV seroconversion rates after 1 year (2018) in the seronegative healthcare workers
Number 221 72 78 71
Men/women 93/128 64/8 8/70 21/50
Median age (interquartile range) (yr) 38 (30, 45) 40 (34, 45) 33.5 (24, 44) 39 (31.5, 44)
CMV-IgG Negative 214 70 76 68
Positive 7 2 2 3
Positivity 3.2% 2.8% 2.6% 4.2%
Of 346 CMV seronegative healthcare workers in June 2017, 221 (63.9%) were followed in June 2018. CMV seropositivities amongmedical doctors, nurses, and other healthcare
workers were not significantly different (Fisher's exact test, p ¼ 0.84).
a Other healthcare workers include pharmacists, medical clerks, and nutrition experts. SD, standard deviation; CI, confidence interval.
Table 2
CMV seroconversion rates after blood and body fluid exposure.
Total Medical doctors Nurses Others
Number 72 38 31 3
Men/women 34/38 30/8 3/28 1/2
Median age (interquartile range) 30 (26, 34.25) 32 (30, 36.5) 26 (23, 29) 26 (25, 35.5)
CMV-IgG Negative 70 37 30 3
Positive 2 1 1 0
Positivity 2.8% 2.6% 3.2% 0%
In 107 CMV seronegative healthcare workers exposed to blood and body fluids, 72 (67.3%) cases were analysed. CMV seroconversion rate was not significantly different from
that observed in the natural course (3.2% vs 2.8%; Fisher's exact test, p ¼ 1.0).
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blood (n¼ 66), saliva (n¼ 4), ascites (n¼ 1); and skin (n¼ 1). Blood
exposure occurred secondary to hollow needles (n ¼ 40), non-
hollow needles (n ¼ 8), unknown needles (n ¼ 8), prick injuries
due to knives (n ¼ 4), and splashes into the mucosa, such as the
eyes (n ¼ 6). All the HCWs were confirmed to be negative for CMV
IgG at the time of BBFE, while the exposure sources were positive
for CMV IgG. The time from BBFE to the examination ranged from
100 to 730 days (median, 356 days [222.75, 490]) after exposure.
Themedian age (IQR) of nurses (26 [23, 29]) was significantly lower
than those of medical doctors (32 [30, 36.5]) (p < 0.001). The pro-
portion of CMV seropositive results in medical doctors, nurses, and
others were 2.6% (1/38), 3.2% (1/31), and 0% (0/3), respectively. In
these two seroconverted cases, the source of body fluid was blood
from hollow needle-stick injuries. CMV seroconversion rates be-
tween the 1-year natural course (Study 1) and that after BBFE
(Study 2) were not significantly different (3.2% vs 2.8%; p ¼ 1.0)
(Fig. 1).
4. Discussion
This study is remarkably new to the literature because it focuses
on the potential risk of CMV infection in HCWs. We have revealed
that CMV seroprevalence among HCWs was approximately 70%,
which showed an increasing tendency with ageing. Among the
seronegative individuals, the annual CMV seroconversion rates
were approximately 3%, with no significant difference among job
categories. Moreover, we demonstrated that the annual CMV
seroconversion rates after BBFE were also approximately 3%, which
was statistically not different from those with natural courses. The
annual CMV seroconversion rates observed in this study were
consistent with previous data obtained from pregnant women:2.1% (24/1122) between first and third trimesters [8], 3.7% (23/621)
between gestational week 17 and birth [9], and average of 2.3% in
pregnancy period [10]. These results might suggest the rarity of
CMV infection through the exposure events in healthcare settings.
Several studies report that current CMV seroprevalence in Eu-
ropean countries is approximately 50%: 41.9% in France [11], 45.6%
in the Netherlands [12], and 56.7% in Germany [6]. In contrast, other
countries have higher positivity rates: 77% in Portugal [13] and
Croatia [14] and 83% in Sweden [15]. In Japan, there have been
several reports of CMV seroprevalence among pregnant women:
78% in 1999 [16], 68% in 2013 [17], 66% in 2003e2012 [18], and
69.1% in 2009e2014 [19]. While, there are limited data on the
general population; 76.6% out of 2400 blood donor samples tested
positive for CMV in 2013 [5]. Compared to these recent data, the
overall CMV seroprevalence observed in our study (70.0%) seems to
be reasonably comparable. A future study widely targeting the
general Japanese population is warranted to clarify the current
trends in CMV positivity.
This study has several limitations. First, this is a single-centre
study with small sample size. Second, we did not examine the
CMV serology immediately after BBFE (the median time from
exposure to examination was 356 days). Thus, the possibility of a
latent CMV infection through medical care was not directly evalu-
ated. Third, CMV is not necessarily excreted in body fluids at any
time, which could have influenced the results. Fourth, CMV posi-
tivity was determined based on CMV IgG alone, and not CMV DNA.
Sequencing analyses would be an interesting means of identifying
the clonality of CMV between the exposed HCWs and the exposure
source. Due to technical and financial difficulties, we did not
perform a molecular investigation. Lastly, the implementation rate
of standard precautions amongmedical doctors and nurses was not
evaluated, which could have influenced CMV transmission.
M. Takao et al. / J Infect Chemother 26 (2020) 681e684684Our investigation did not suggest a possibility of CMV infection
through daily patient care, although HCWs are at an increased risk
of exposure to various infectious agents. However, due to several
limitations, the present study does not deny the risk of CMV
occupational infection in HCWs, and further studies are warranted
to verify our results.
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